Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vanlev gets July panel date

The FDA's Cardiovascular and Renal Drugs Advisory Committee will review on July 19 an NDA from Bristol-Myers (BMY) for its

Read the full 208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE